14-day tailored PCR-guided triple therapy versus 14-day non-Bismuth concomitant quadruple therapy for Helicobacter pylori eradication: A multicenter, open-label randomized noninferiority controlled trial.

Background: The systematic use of susceptibility testing and tailored first-line treatment for Helicobacter pylori eradication has yet to be established.

Aim: To compare 14-day tailored PCR-guided triple therapy to 14-day non-Bismuth concomitant quadruple therapy for first-line Helicobacter pylori eradication.

Patients And Methods: We performed a multicenter, parallel-group, randomized noninferiority controlled trial.